A Phase 1/2 interventional study of Ascorbate in Soft Tissue Sarcoma, sponsored by Mohammed Milhem. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-18.
Sponsored by Mohammed Milhem · Phase 1/2, Interventional, and Treatment
This is a single-arm open-label phase Ib/II clinical study assessing the efficacy of concurrent high dose ascorbate in combination with radiotherapy in patients with locally advanced, resectable, high grade sarcomas.
Phase Ib:
The phase Ib portion of this study is to ensure the safety and tolerability of high dose ascorbate in combination with external beam radiation therapy (EBRT) as assessed by incidence of dose-limiting toxicities (DLT). EBRT will be given at the standard dose for resectable soft tissue sarcomas according to the NCCN sarcoma guidelines.2 Patients will receive 50 Gy over 5 weeks, during which time they will be receiving three times a week IV high dose ascorbate. IV ascorbate infusions will be continued until the end of radiation therapy. Surgery will be performed 4-6 weeks from the end of radiation to allow for adequate tissue healing and resolution of acute toxicities.
Phase 2:
The phase 2 part of the study will provide an estimate of the relative treatment effect of pharmacological ascorbate in combination with preoperative EBRT in subjects with locally advanced, resectable, extremity, trunk or retroperitoneal high grade sarcomas, as measured by pathological response rates.
As above, patients will receive the first dose of pharmacological ascorbate intravenously on day 1 of week 1 provided no reactions are seen to the test dose. This will be followed by 3 times a week dosing at Dose 0 until completion of EBRT. Standard doses of radiation for resectable soft tissue sarcomas according to the NCCN sarcoma guidelines will be administered.2 Patients will receive preoperative radiation at a dose of 50 Gy over 5 weeks starting on week 1 day 1. Subjects will be followed either by clinic visit or phone contact every 12 weeks for approximately 24 months after the end of the treatment phase, at which time the initial survival data and disease recurrence will be assessed.
1,607 studies on the registry are indexed under Sarcoma; 366 are open to participants now.
This study's enrollment of 25 is below the median of 40 across 1,255 interventional studies indexed under Sarcoma.
Browse Sarcoma studies →Mohammed Milhem is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
confirmed diagnosis of locally advanced soft tissue sarcoma of extremity, trunk or retroperitoneum that is unresectable with clear wide margins, for which preoperative radiotherapy is considered appropriate
- Including (stage IV) disease for which radiotherapy and surgical resection of the primary tumor are indicated.
Patient must have :
Exclusion Criteria:
Inadequate organ function within 21 days of Day 1 of study as defined by:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumour measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumour visible on a scan does not by itself rule you out.
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumour measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumour visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive radiation therapy over 5 weeks, during which time they will be receiving ascorbate infusions three times a week. Ascorbate infusions will be continued until the end of radiation therapy. Surgery will be performed 4-6 weeks from the end of radiation.
Drug: Ascorbate
Participants will receive radiation therapy over 5 weeks, during which time they will be receiving intravenous (IV) ascorbate infusions three times a week. Ascorbate infusions will be continued until the end of radiation therapy. Surgery will be performed 4-6 weeks from the end of radiation.
Drug: Ascorbate
Phase 1 dose escalation: 75gm IV three times a week Phase II portion: 75gm IV three times a week if no dose limiting toxicities are experienced in the Phase I portion. Otherwise, ascorbate dose will be deescalated to 62.5 gm IV
Also known as: Ascorbic Acid, Vitamin C, Pharmacological ascorbate
Number of Participants That Experienced Dose Limiting Toxicities (DLTs) Using CTCAE, Version 4.0
To examine the toxicity related to the therapy by measuring the number attributed adverse event (definite, probable or possible) according to CTCAE version 4.0.
Time frame: Start of treatment up to 4 weeks after the last ascorbate infusion
Number of Participants With Pathologic Tumor Necrosis ≥ 95% Following Concurrent Radiation Therapy and Ascorbate
To estimate the efficacy of neoadjuvant ascorbate and radiotherapy as assessed by the pathological complete response rates (pCR) in subjects with locally advanced high grade soft tissue sarcomas.
Time frame: Start of treatment up to 6 weeks after the last ascorbate infusion
Event-Free Survival at 2 Years
Event-free survival is defined as the time from treatment initiation until progression which precludes surgery, recurrence or death due to any cause. Otherwise, patients are censored at last disease assessment.
Time frame: Enrollment or start of treatment up to 2 years following end of treatment
Overall Response Rate
Overall response rate (ORR) is the percentage of patients with a complete or partial response preoperatively as measured by RECIST 1.1 or a later tool for monitoring disease progression.
Time frame: Enrollment or start of treatment up to 2 years following end of treatment
Overall Survival at 2 Years
Overall survival is defined as the time from treatment initiation to death due to any cause. Patients still alive are censored at last date known to be alive.
Time frame: Enrollment or start of treatment up to 2 years following end of treatment
Skin Toxicity
Pathologist to grade radiation related skin toxicity.
Time frame: Within two years following end of treatment
Labile Iron
To measure labile iron using T2\* imaging sequence on MRI pre and post ascorbate treatments and compare with serum iron measurements
Time frame: Within two years following end of treatment
Evaluate Diffusion Weighted Imaging Sequences
To evaluate diffusion weighted imaging sequences on MRI in pre and post treatment tumors and correlate it with necrosis and survival
Time frame: Within two years following end of treatment
Participants were recruited from the Principal Investigator's and Sub-Investigator's clinics at Holden Comprehensive Cancer Center.
| Milestone | Phase I: Ascorbate 75 mg IV Infusion | Phase II: Ascorbate 75 mg IV Infusion |
|---|---|---|
| Started | 6 | 19 |
| Completed | 6 | 18 |
| Not completed | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
To examine the toxicity related to the therapy by measuring the number attributed adverse event (definite, probable or possible) according to CTCAE version 4.0.
| participants | Phase I: Ascorbate 75 mg IV Infusion |
|---|---|
| Number of Participants That Experienced Dose Limiting Toxicities (DLTs) Using CTCAE, Version 4.0 | 0 |
To estimate the efficacy of neoadjuvant ascorbate and radiotherapy as assessed by the pathological complete response rates (pCR) in subjects with locally advanced high grade soft tissue sarcomas.
| Participants | Phase I: Ascorbate 75 mg IV Infusion | Phase II: Ascorbate 75 mg IV Infusion |
|---|---|---|
| Number of Participants With Pathologic Tumor Necrosis ≥ 95% Following Concurrent Radiation Therapy and Ascorbate | 2 | 1 |
Event-free survival is defined as the time from treatment initiation until progression which precludes surgery, recurrence or death due to any cause. Otherwise, patients are censored at last disease assessment.
| Cumulative Probability | Phase I: Ascorbate 75 mg IV Infusion | Phase II: Ascorbate 75 mg IV Infusion |
|---|---|---|
| Event-Free Survival at 2 Years | 100 (100 to 100) | 46 (23 to 67) |
Overall response rate (ORR) is the percentage of patients with a complete or partial response preoperatively as measured by RECIST 1.1 or a later tool for monitoring disease progression.
| Participants | Phase I: Ascorbate 75 mg IV Infusion | Phase II: Ascorbate 75 mg IV Infusion |
|---|---|---|
| Overall Response Rate | 0 | 2 |
Overall survival is defined as the time from treatment initiation to death due to any cause. Patients still alive are censored at last date known to be alive.
| Cumulative Probability | Phase I: Ascorbate 75 mg IV Infusion | Phase II: Ascorbate 75 mg IV Infusion |
|---|---|---|
| Overall Survival at 2 Years | 100 (100 to 100) | 74 (48 to 88) |
Pathologist to grade radiation related skin toxicity.
| participants | Phase I: Ascorbate 75 mg IV Infusion | Phase II: Ascorbate 75 mg IV Infusion |
|---|---|---|
| Grade 0 | 4 | 9 |
| Grade 1 | 1 | 2 |
| Grade 2 | 1 | 6 |
| Grade 3 | 0 | 2 |
To measure labile iron using T2\* imaging sequence on MRI pre and post ascorbate treatments and compare with serum iron measurements
| Participants | Phase I: Ascorbate 75 mg IV Infusion | Phase II: Ascorbate 75 mg IV Infusion |
|---|---|---|
| Labile Iron | 0 | 0 |
To evaluate diffusion weighted imaging sequences on MRI in pre and post treatment tumors and correlate it with necrosis and survival
| Participants | Phase I: Ascorbate 75 mg IV Infusion | Phase II: Ascorbate 75 mg IV Infusion |
|---|---|---|
| Evaluate Diffusion Weighted Imaging Sequences | 0 | 0 |
Collected over Adverse events (AE) were collected after signing of Informed Consent Form and continued through the 30-day follow up period after treatment is discontinued, up to 12 weeks. Deaths (overall survival) was assessed for up to 2 years following the initiation of treatment.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase I: Ascorbate 75 mg IV Infusion | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Phase II: Ascorbate 75 mg IV Infusion | 5/19 (26.3%) | 4/19 (21.1%) | 18/19 (94.7%) |
| Event | Phase I: Ascorbate 75 mg IV Infusion | Phase II: Ascorbate 75 mg IV Infusion |
|---|---|---|
| Abdominal painGastrointestinal disorders | 0/6 | 1/19 |
| Jejunal obstructionGastrointestinal disorders | 0/6 | 1/19 |
| FeverGeneral disorders and administration site conditions | 0/6 | 1/19 |
| BacteremiaInfections and infestations | 0/6 | 1/19 |
| Kidney infectionInfections and infestations | 0/6 | 1/19 |
| DehydrationMetabolism and nutrition disorders | 0/6 | 1/19 |
| Metabolism and nutrition disorders - Other, specifyMetabolism and nutrition disorders | 0/6 | 1/19 |
| Generalized muscle weaknessMusculoskeletal and connective tissue disorders | 0/6 | 1/19 |
| Tumor painNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/6 | 1/19 |
| Event | Phase I: Ascorbate 75 mg IV Infusion | Phase II: Ascorbate 75 mg IV Infusion |
|---|---|---|
| NauseaGastrointestinal disorders | 4/6 | 9/19 |
| Lymphocyte count decreasedInvestigations | 4/6 | 7/19 |
| FatigueGeneral disorders and administration site conditions | 3/6 | 5/19 |
| Investigations - Other, specifyInvestigations | 3/6 | 8/19 |
| HypertensionVascular disorders | 3/6 | 2/19 |
| AnemiaBlood and lymphatic system disorders | 2/6 | 7/19 |
| Dry mouthGastrointestinal disorders | 2/6 | 2/19 |
| Dermatitis radiationInjury, poisoning and procedural complications | 2/6 | 3/19 |
| Alanine aminotransferase increasedInvestigations | 2/6 | 2/19 |
| Neutrophil count decreasedInvestigations | 2/6 | 1/19 |
| Age, Categorical(Participants) | Phase I: Ascorbate 75 mg IV Infusion | Phase II: Ascorbate 75 mg IV Infusion | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 4 | 5 | 9 |
| >=65 years | 2 | 14 | 16 |
| Age, Continuous(years) | Phase I: Ascorbate 75 mg IV Infusion | Phase II: Ascorbate 75 mg IV Infusion | Total |
|---|---|---|---|
| Mean | 60 (39 to 85) | 67 (42 to 87) | 65 (39 to 87) |
| Sex: Female, Male(Participants) | Phase I: Ascorbate 75 mg IV Infusion | Phase II: Ascorbate 75 mg IV Infusion | Total |
|---|---|---|---|
| Female | 4 | 7 | 11 |
| Male | 2 | 12 | 14 |
| Ethnicity (NIH/OMB)(Participants) | Phase I: Ascorbate 75 mg IV Infusion | Phase II: Ascorbate 75 mg IV Infusion | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 6 | 19 | 25 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Phase I: Ascorbate 75 mg IV Infusion | Phase II: Ascorbate 75 mg IV Infusion | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 1 |
| White | 5 | 19 | 24 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Phase I: Ascorbate 75 mg IV Infusion | Phase II: Ascorbate 75 mg IV Infusion | Total |
|---|---|---|---|
| United States | 6 | 19 | 25 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ascorbic Acid
Mohammed Milhem